UNSPSC 51422205: Flunarizine

This classification denotes a histamine-1 receptor antagonist and calcium channel blocker with the molecular formula C26H26F2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R7PLA2DM0J, chemically known as piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (e)- but generally known as flunarizine, which bears US NIH Compound Identifier 941361. European Medicines Agency schedules Flunarizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07707MIG.

UNSPSC 51422205 Flunarizine, a Commodity code, nominally covers a specific antihistamine pharmaceutical product, but the recent state and local solicitations tagged under this code reflect a broader pharmaceutical procurement practice: the sourcing of naloxone (an opioid antagonist) and drug deactivation systems by county health agencies, and the exploration of direct-to-manufacturer prescription delivery models by state pharmacy benefit programs. State and local governments buy pharmaceutical products and related health services under this code through both transactional procurement (naloxone and safety equipment purchases for community health programs) and strategic capability-assessment mechanisms (RFI-stage market research into alternative pharmacy distribution channels). Issuing bodies include county health departments and state health and human services commissions, reflecting the mix of operational purchasing at the county level and program-design activity at the state level.

Recent activity centers on Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023 and a two-year contract term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor information on direct-to-manufacturer prescription fulfillment capabilities to support a Therapeutic Pharmacy Initiative, signaling state-level interest in alternative pharmacy benefit supply chains outside traditional pharmacy benefit manager and group purchasing organization channels. Neither the Seminole County nor the Texas HHS opportunity specifies set-aside designations for disadvantaged enterprises.